Almécija AC, Pérez V, Baro M, Guerra-García P, Vivanco JL. Atypical Autoimmune Hematological Disorders in a Patient With Kabuki Syndrome. J Pediatr Hematol Oncol. 2018 Apr 20 [PubMed]

Alonso CM, Llop M, Sargas C, Pedrola L, Panadero J, Hervás D, et al. Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics. J Mol Diagn. 2018 Dec 18

Álvarez Larrán A, Martínez D, Arenillas L, Rubio A, Arellano Rodrigo E, Hernández Boluda JC, et al. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes. J Clin Pathol. 2018;71(11):975-80 [PubMed]

Arana P, Paiva B, Cedena MT, Puig N, Cordón L, Vidriales MB, et al. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia. 2018;32(4):971–8 [PubMed]

Arenas Cortés A, Ayala Díaz R, Hernández Campo P, Gorrochategui J, Primo D, Robles A, et al. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. Haematologica. 2018 Dec 13

Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al. Increased survival due to lower toxicity for high risk T-cell acute lymphoblastic leukemia patients in 2 consecutive pediatric-inspired PETHEMA Trials. Eur J Haematol. 2018 Sep 29

Blade J, Calleja MA, Lahuerta JJ, Poveda JL, De Paz HD, Lizán L. Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. BMJ Open. 2018;8(2):e018850 [PubMed]

Carreño Tarragona G, Cedena T, Montejano L, Alonso R, Miras F, Valeri A, et al. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies. Transfus Med. 2018 Jan 25 [PubMed]

Cedena MT, Rapado I, Santos Lozano A, Ayala R, Onecha E, Abaigar M, et al. Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2018;9(56):30936.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209-17 [PubMed]

Díez Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, et al. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. Br J Haematol. 2018;181(3):350-9 [PubMed]

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, et al. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018;32(6):1404-13.

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, et al. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leuk Lymphoma. 2018;59(5):1113–20 [PubMed]

Fernández L, Leivas A, Valentín J, Escudero A, Corral D, De Paz R, et al. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment? Transfusion. 2018;58(6):1340-7 [PubMed]

García Ortiz A, Serrador JM. Nitric oxide signaling in T cell-mediated immunity. Trends Mol Med. 2018;24(4):412–27 [PubMed]

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018;4(10):1389-97.

Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez Marzo P, et al. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018;11(1):96.

Giraldo P, Andrade Campos M, Alfonso P, Irún P, Atutxa K, Acedo A, et al. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. Blood Cells Mol Dis. 2018;68:173–9 [PubMed]

González Vicent M, Sanz J, Fuster JL, Cid J, De Heredia CD, Morillo D, et al. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). Transfus Med Rev. 2018 Mar 3 [PubMed]

Hernández Boluda JC, Correa JG, Álvarez Larrán A, Ferrer Marín F, Raya JM, Martínez López J, et al; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol. 2018;181(3):397-400 [PubMed]

Hernández Boluda JC, Pereira A, Correa JG, Álvarez Larrán A, Ferrer Marín F, Raya JM, et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2018;32(2):553–5 [PubMed]

Hernández Boluda JC, Pereira A, Correa J G, Álvarez Larrán A, Ferrer Marín F, Raya JM, et al. Prognostic risk models for transplant decision-making in myelofibrosis. Ann Hematol. 2018;97(5):813–20 [PubMed]

Hernández Boluda JC, Pereira A, Pastor Galán I, Álvarez Larrán A, Savchuk A, Puerta JM, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018;8(10):91

Jiménez Ubieto A, Grande C, Caballero D, Yáñez L, Hernández García MT, Novelli S, et al. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplant. 2018;53(6):780-3 [PubMed]

Jiménez Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández García MT, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018;36(5):765-72.

Labrador J, Luño E, Vellenga E, Brunet S, González Campos J, Chillón MC, et al. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leuk Lymphoma. 2018;1-10

Li N, López MA, Linares M, Kumar S, Oliva S, Martínez López J, et al. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2018 Sep 11

López Anglada L, Cueto Felgueroso C, Rosiñol L, Oriol A, Teruel AI, López de la Guía A, et al. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS ONE. 2018 Sep 7;13(9):e020339.

Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, et al. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. Br J Haematol. 2018;183(3):375-84.

Martínez Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez Veiga R, Esteve J, et al. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Ann Hematol. 2018;97(5):763–72 [PubMed]

Martínez Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez Veiga R, Esteve J, et al. Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Ann Hematol. 2018;97(5):923 [PubMed]

Martínez Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez Oteyza J, García Boyero R, et al. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2018;76:1-10

Martínez Cuadrón D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A, et al. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia. 2018;32(1):21–9 [PubMed]

Martínez Laperche C, Kwon M, Franco Villegas AC, Chillón MC, Castro N, Anguita E, et al. Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. Br J Haematol. 2018;181(4):542-6.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-28 [PubMed]

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez López J, García Sanz R, Oriol A, et al. A novel nano-immunoassay method for quantification of proteins from CD138 purified myeloma cells: biological and clinical utility. Haematologica. 2018;103(5):880-9 [PubMed]

Montalbán C, Díaz López A, Martín A, Baile M, Sánchez JM, Sancho JM, et al. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. Br J Haematol. 2018;182(4):534-41 [PubMed]

Moreno Carralero MI, Horta Herrera S, Morado Arias M, Ricard Andrés MP, Lemes Castellano A, Abio Calvete M, et al. Clinical and genetic features of congenital dyserythropoietic anemia (CDA). Eur J Haematol. 2018;101(3):368-78 [PubMed]

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al.; International Myeloma Working Group. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2018;29(4):1074 [PubMed]

Osorio S, Escudero Vilaplana V, Gómez Centurión I, Pérez López R, Ayala R, Vall Llovera F, et al. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? Ann Hematol. 2018;97(11):2089-98 [PubMed]

Pérez Rodríguez A, Batlle J, Corrales I, Borràs N, Rodríguez Trillo Á, Lourés E, et al. Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE. 2018;13(6):e0197876 [PubMed]

Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, et al. A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Oncotarget. 2018;9(40):26019–31 [PubMed]

Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, et al. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia. 2018 Dec 12

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121–8 [PubMed]

Redondo AM, Valcárcel D, González Rodríguez AP, Suárez Lledó M, Bello JL, Canales M, et al. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. 2018 Dec 12

Ribera JM, García O, Gil C, Mercadal S, García Cadenas I, Montesinos P, et al. Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2018;68:79–84 [PubMed]

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(7):1634-43

Rodríguez Otero P, Mateos MV, Martínez López J, Martín Calvo N, Hernández MT, Ocio EM, et al. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia. 2018 Feb 23 [PubMed]

Ruiz Heredia Y, Sánchez Vega B, Onecha E, Barrio S, Alonso R, Martínez Ávila JC, et al. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica. 2018;103(11):e544-e548 [PubMed]

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al.; EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-57 [PubMed]

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107–20 [PubMed]

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J. 2018;8(12):123

Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 2018;422:107–17 [PubMed]